Joanna M. Brell

4.2k total citations · 1 hit paper
40 papers, 1.7k citations indexed

About

Joanna M. Brell is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Joanna M. Brell has authored 40 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Joanna M. Brell's work include Cancer Treatment and Pharmacology (14 papers), Colorectal Cancer Treatments and Studies (10 papers) and Pancreatic and Hepatic Oncology Research (9 papers). Joanna M. Brell is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Colorectal Cancer Treatments and Studies (10 papers) and Pancreatic and Hepatic Oncology Research (9 papers). Joanna M. Brell collaborates with scholars based in United States, Malaysia and Germany. Joanna M. Brell's co-authors include Christopher H. Crane, Al B. Benson, Steven R. Alberts, Higinia R. Cárdenes, Ramesh K. Ramanathan, Lynne I. Wagner, David Cella, Patrick J. Loehrer, Patrick J. Flynn and Yang Feng and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Joanna M. Brell

36 papers receiving 1.7k citations

Hit Papers

Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in... 2011 2026 2016 2021 2011 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
    2011 604 citations Patrick J. Loehrer, Yang Feng et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joanna M. Brell United States 17 1.2k 502 422 337 268 40 1.7k
K. Syrigos Greece 23 1.1k 1.0× 638 1.3× 388 0.9× 288 0.9× 165 0.6× 73 1.9k
Stanislas Ropert France 26 1.1k 0.9× 757 1.5× 729 1.7× 296 0.9× 299 1.1× 67 2.5k
Georg Pfeiler Austria 24 952 0.8× 286 0.6× 532 1.3× 527 1.6× 187 0.7× 91 1.7k
Kyung Hwan Kim South Korea 26 994 0.8× 485 1.0× 429 1.0× 326 1.0× 153 0.6× 95 2.2k
F. Ries Luxembourg 21 622 0.5× 325 0.6× 330 0.8× 256 0.8× 212 0.8× 70 1.7k
David Chu United States 27 1.1k 0.9× 674 1.3× 1.1k 2.6× 428 1.3× 147 0.5× 56 2.8k
Ralf J. Rieker Germany 27 694 0.6× 435 0.9× 738 1.7× 293 0.9× 369 1.4× 91 2.2k
Felix E. de Jongh Netherlands 22 1.2k 1.0× 448 0.9× 250 0.6× 385 1.1× 355 1.3× 34 2.1k
Yuichiro Takeda Japan 20 780 0.7× 629 1.3× 387 0.9× 118 0.4× 152 0.6× 123 1.6k
Florian Hohla Austria 23 1.0k 0.9× 411 0.8× 349 0.8× 330 1.0× 592 2.2× 41 1.8k

Countries citing papers authored by Joanna M. Brell

Since Specialization
Citations

This map shows the geographic impact of Joanna M. Brell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanna M. Brell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanna M. Brell more than expected).

Fields of papers citing papers by Joanna M. Brell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joanna M. Brell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanna M. Brell. The network helps show where Joanna M. Brell may publish in the future.

Co-authorship network of co-authors of Joanna M. Brell

This figure shows the co-authorship network connecting the top 25 collaborators of Joanna M. Brell. A scholar is included among the top collaborators of Joanna M. Brell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joanna M. Brell. Joanna M. Brell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Atkins, M.B., Sandra J. Lee, Bartosz Chmielowski, et al.. (2025). DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results.. Journal of Clinical Oncology. 43(16_suppl). 9506–9506.
2.
Upshaw, Jenica, Anne O’Neill, Joseph R. Carver, et al.. (2018). Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal. Clinical Colorectal Cancer. 18(1). 44–51. 22 indexed citations
3.
Lewis, Mark A., Fengmin Zhao, Desirée Jones, et al.. (2015). Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study. Journal of Pain and Symptom Management. 49(6). 1016–1024. 20 indexed citations
4.
Jones, Desirée, Fengmin Zhao, Joanna M. Brell, et al.. (2014). Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. Journal of Cancer Survivorship. 9(1). 1–10. 27 indexed citations
5.
Brell, Joanna M., Smitha Krishnamurthi, Linda Rath, et al.. (2012). Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70(4). 547–553. 10 indexed citations
6.
Cleeland, Charles S., Jeff Allen, Samantha Roberts, et al.. (2012). Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nature Reviews Clinical Oncology. 9(8). 471–478. 104 indexed citations
7.
Wang, Xiaomin, Tanya Lehky, Joanna M. Brell, & Susan G. Dorsey. (2012). Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 59(1). 3–9. 176 indexed citations
8.
Loehrer, Patrick J., Yang Feng, Higinia R. Cárdenes, et al.. (2011). Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology. 29(31). 4105–4112. 604 indexed citations breakdown →
9.
Ricart, Alejandro D., Edward Ashton, Matthew M. Cooney, et al.. (2011). A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 68(4). 959–970. 27 indexed citations
10.
Brell, Joanna M.. (2010). Prolonged QTc Interval in Cancer Therapeutic Drug Development: Defining Arrhythmic Risk in Malignancy. Progress in Cardiovascular Diseases. 53(2). 164–172. 39 indexed citations
11.
Nock, Charles, Joanna M. Brell, Joseph A. Bokar, et al.. (2009). A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors. Investigational New Drugs. 29(1). 126–130. 17 indexed citations
12.
Brell, Joanna M., Khalid Matin, Terry Evans, et al.. (2009). Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer. Oncology. 76(4). 270–274. 29 indexed citations
13.
Dowlati, Afshin, James Posey, Ramesh K. Ramanathan, et al.. (2009). Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers. Cancer Chemotherapy and Pharmacology. 65(1). 73–78. 10 indexed citations
14.
Gibbons, Joseph, Smitha Krishnamurthi, Joanna M. Brell, et al.. (2008). Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Investigational New Drugs. 27(5). 453–460. 18 indexed citations
15.
Brell, Joanna M., Smitha Krishnamurthi, Milind Javle, et al.. (2008). A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemotherapy and Pharmacology. 63(5). 851–857. 11 indexed citations
16.
Cooney, Matthew M., Afshin Dowlati, Joanna M. Brell, et al.. (2008). Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Investigational New Drugs. 26(4). 355–362. 16 indexed citations
17.
Krishnamurthi, Smitha, Joanna M. Brell, Charles L. Hoppel, et al.. (2008). Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemotherapy and Pharmacology. 63(3). 441–450. 9 indexed citations
18.
Cooney, Matthew M., Josep Garcia, Joanna M. Brell, et al.. (2007). A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors. Journal of Clinical Oncology. 25(18_suppl). 15532–15532. 11 indexed citations
19.
Sarantopoulos, John, et al.. (2006). 359 POSTER Pharmacokinetic and pharmacodynamic effects of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors. European Journal of Cancer Supplements. 4(12). 111–112. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K. Syrigos Breakdown of academic impact, for papers by Stanislas Ropert Breakdown of academic impact, for papers by Georg Pfeiler Breakdown of academic impact, for papers by Kyung Hwan Kim Breakdown of academic impact, for papers by F. Ries Breakdown of academic impact, for papers by David Chu Breakdown of academic impact, for papers by Ralf J. Rieker Breakdown of academic impact, for papers by Felix E. de Jongh Breakdown of academic impact, for papers by Yuichiro Takeda Breakdown of academic impact, for papers by Florian Hohla
Rankless by CCL
2026